Pharmacodynamics (PD) investigates the effects of an active substance in the organism and the mechanisms by which they are brought about. It describes desired pharmacological effects as well as adverse effects and relates them, as far as possible, to dose or exposure. It thus provides a basis for classifying the biological activity, benefits, and risks of a developmental medicinal product.
Mechanism of action and pharmacological effects
The starting point of pharmacodynamics is the interaction of an active substance with a target structure, for example a receptor, enzyme, ion channel, or transporter. This can result in directly measurable changes or downstream signaling pathways. Primary pharmacodynamics investigates the intended effect at the therapeutic target. Secondary pharmacodynamics considers further effects, including interactions with other target structures, which can contribute to the safety assessment.
Non-clinical investigations provide the biological justification for the entry into clinical development. In oncology, ICH S9 requires, among other things, a preliminary characterization of the mechanism of action, the dependence on treatment intervals, and the anti-tumor activity before a phase I trial. In First-in-Human trials, the available non-clinical pharmacological, PK, and safety information is combined to assess risks and appropriate measures in the protocol.
Dose, exposure and effect relationships
The dose-response relationship describes how an effect changes with the administered amount. Frequently, however, the dose is only an indirect starting point: the concentration at or near the site of action can be decisive. An exposure-response relationship therefore links measured concentrations to a pharmacodynamic endpoint. The effect can increase with increasing concentration, reach a plateau, or only occur with a time delay.
Models can, for example, describe a maximum achievable effect and the concentration at which a certain proportion of this effect is achieved. They do not replace robust data, but help to plan measurement time points, dose levels, and the selection of further investigations. ICH E4 emphasizes that the dose-response information for efficacy and adverse effects should support safe and effective use. The selection of a dose thereby accounts for pharmacokinetic and pharmacodynamic variability as well as patient-related factors.
For the analysis, a distinction must be made as to whether an endpoint reflects an early target modulation, an intermediate pharmacological marker, or a clinical benefit. A measurable effect can support the assumption regarding the mechanism of action, but is not automatically to be evaluated as a clinical benefit. For active substances with delayed or irreversible effects, the observation period must be chosen such that the onset of effect, duration, and possible recovery become recognizable.
The selection of an endpoint therefore depends on the biological hypothesis and the stage of development.
Differentiation from pharmacokinetics
Pharmacodynamics focuses on the reaction of the biological system to the medicinal product: such as target structure binding, a biomarker, or a clinical effect. Pharmacokinetics, in contrast, maps the pathway of the active substance through the body, including absorption, distribution, metabolism, and excretion. It thus explains the concentration profile, not the effect itself.
Both disciplines complement each other without one being derivable from the other. A pharmacodynamic effect can vary between persons at the same dose; conversely, the same concentrations can trigger different effects. PK/PD analyses combine the separately collected information and make these differences visible for dose decisions.
Relevance for clinical trials
Pharmacodynamic endpoints are particularly important in early trials when biological activity and a plausible dose range are being investigated. Depending on the mechanism of action, biomarkers, laboratory values, physiological metrics, imaging procedures, or functional tests come into consideration. The endpoint must be analytically and pre-analytically validated, its temporal relation to administration justified, and its clinical validity appropriately classified. In the case of a steep dose-response or exposure-response relationship, small changes in dose or exposure can be relevant to safety.
Full-service CROs such as Mediconomics support the selection and operational integration of pharmacodynamic endpoints, the planning of sampling and measurement time points, site management, and data quality. They coordinate interfaces between clinical conduct, laboratories, data management, biostatistics, and medical writing so that the analysis of biomarkers and clinical observations flows traceably into study reports and dose decisions.
Frequently Asked Questions (FAQ)
What is measured with a pharmacodynamic biomarker?
A pharmacodynamic biomarker captures a biological response to the administration of a medicinal product. Its suitability depends on whether it sufficiently reliably reflects the mechanism of action or a relevant effect.
Why are desired and adverse effects considered together?
The clinically appropriate dose should enable a favorable benefit-risk balance. Therefore, signs of efficacy and safety endpoints are evaluated together with dose and exposure.
Is evidence of biological activity already evidence of efficacy?
No. Biological activity can support mechanism plausibility, but does not replace the evidence of a clinically relevant benefit required for the respective indication.
Regulatory references
- ICH S9, Nonclinical Evaluation for Anticancer Pharmaceuticals – describes the non-clinical pharmacological basis for early clinical development in oncology.
- ICH E4, Dose-Response Information to Support Drug Registration – covers dose-response relationships for desired and adverse effects.
- ICH M3(R2), Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals – maps primary and safety pharmacology studies in the development program.
- EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products – requires a risk-based justification of starting dose, dose escalation, and maximum exposure incorporating PD data.